Agence France-PresseMay 6, 2021 11:00:46 AMT
On Thursday, the actual largest actual study of the Pfizer / BioNTec vaccine confirmed that jab provided more than 95 percent protection against Covid-19, but found that levels dropped significantly when people received only one of the two prescribed doses. According to the authors of the study, Israel’s National Vaccination Campaign, it actually showed evidence that the pandemic can be stopped with rapid, global vaccination programs. An analysis of public health data from Israel – one of the countries with the highest proportion of vaccinated adults – showed that the vaccine was very effective even in protecting the elderly at a time when a more contagious English variant was predominant, according to published results. that Lancet medical diary.
By early April, nearly five million people in Israel had received two doses of Pfizer / BioNTech, more than 70 percent of the population.
The study found that two doses provided 95.3 percent protection against infections and 96.7 protection against death seven days after the second dose.
After 14 days, hedging rose to 96.5 percent and 98 percent, respectively.
But protection was significantly weaker when people received only one dose of the vaccine.
Between seven and 14 days after the first dose, protection against infections was found to be 57.7 percent and protection against death 77 percent.
The authors said a single dose may provide shorter protection, especially in an environment where new viral alternatives are emerging.
“Importantly, the study shows that two doses of the vaccine significantly increase immunity and protection,” said Jonathan Ball, a professor of molecular virology at the University of Nottingham who was not involved in the study. “That’s why it’s important that people get both doses.”
During the analysis period, there were 232,268 confirmed Covid-19 infections, and nearly 95 percent of the samples tested were found to have an English variant of B117. There were 4481 serious infections and 1113 deaths.
The team behind the study said they were unable to study the impact of the South African variant, which has also been identified in Israel.
Prior to Thursday, the largest actual study of the Pfizer / BioNTec vaccine, including in Israel, was nearly five times smaller, involving 1.2 million people.
Writing in a commentary article, Eyal Lesham of Chaim Sheba Medical Center and Annelies Wilder-Smith of the London School of Hygiene and Tropical Medicine said the research findings “suggest that high vaccine levels could provide access to a pandemic”.
“Unfortunately, rapid population coverage cannot be easily replicated in many other countries,” said a couple who were not included in the Lancet study. “Worldwide use of (Pfizer / BioNTech) vaccine is limited by delivery problems, high costs and very cold chain storage requirements.”